Genmab ASFRA:GE91 -2.42%93 EV-to-FCF is 24.41 as of Jul. 08, 2026, which is 48% below its 10-year median of 46.83. GuruFocus rates FRA:GE91 with a GF Score™ of 93/100 and a GF Value™ of €29.34 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 327 Biotechnology companies, Genmab AS ranks worse than 59.94% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Genmab AS's Enterprise Value is €18,170 Mil.
Genmab AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €744 Mil. Therefore, Genmab AS's EV-to-FCF for today is 24.41.
The historical rank and industry rank for Genmab AS's EV-to-FCF or its related term are showing as below:
FRA:GE91'
s EV-to-FCF Range Over the Past 10 Years
Min: 7.32 Med: 46.83 Max: 325.29
Current: 25.49
During the past 13 years, the highest EV-to-FCF of Genmab AS was 325.29. The lowest was 7.32. And the median was 46.83.
FRA:GE91's EV-to-FCF is ranked worse than 59.94% of 327
companies
in the Biotechnology industry
Industry Median: 16.69
vs FRA:GE91: 25.49
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genmab AS's share price for today is €24.20.
Genmab AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.132.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Genmab AS EV-to-FCF Related Terms
Genmab AS EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Genmab AS's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GE91 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Genmab AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Genmab AS's EV-to-FCF falls into.
Genmab AS's current Enterprise Value is €18,170 Mil.
Genmab AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €744 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (FRA:GE91) has a EV-to-FCF of 24.41 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Genmab AS and its competitors. This is 48% below median its historical median of 46.83. Over the past decade, Genmab AS's EV-to-FCF has ranged from 7.32 to 325.29. According to the industry distribution chart, Genmab AS ranks #196 out of 327 companies in the Biotechnology industry, placing it in the top 59.9%.
Is Genmab AS's EV-to-FCF too high?
Genmab AS's current EV-to-FCF of 24.41 is 48% below median its 10-year median of 46.83. Over the past 10 years, this metric has ranged from a low of 7.32 to a high of 325.29. The Biotechnology industry median EV-to-FCF is 16.69. Genmab AS's value of 24.41 is 46.3% above this industry median. Based on the distribution chart, Genmab AS ranks #196 out of 327 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genmab AS has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #196 out of 327 companies for EV-to-FCF. This places Genmab AS in the lower half of its industry. The industry median EV-to-FCF is 16.69. Genmab AS's value of 24.41 is 46.3% above this benchmark. Historically, Genmab AS's own EV-to-FCF has ranged from 7.32 to 325.29 over the past decade. While the company's 10-year median is 46.83 vs. the industry median of 16.69, Genmab AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.69, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genmab AS's current EV-to-FCF of 24.41 is 46.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Genmab AS and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current EV-to-FCF is 24.41, which is 48% below median its own 10-year median of 46.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (FRA:GE91) is currently considered Modestly Undervalued. The stock's GF Value™ is €29.34, compared to a current price of €24.20 — trading 17.5% below its estimated fair value. The current EV-to-FCF is 24.41, which is 48% below median its 10-year median of 46.83 and 46.3% above the Biotechnology industry median of 16.69. Genmab AS's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Genmab AS (FRA:GE91), the current EV-to-FCF is 24.41 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (FRA:GE91) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of €24.20 is trading 17.5% below its estimated GF Value™ of €29.34.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for FRA:GE91:
EV-to-FCF: 24.41 (48% below median its 10-year median of 46.83)
GF Value™: €29.34 vs. price of €24.20 (17.5% below fair value)
Industry Position: 46.3% above the Biotechnology median (#196 of 327)
No single metric tells the full story. See the FRA:GE91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score
Get the complete analysis for FRA:GE91
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GE91 has been successfully added to your 
